Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies
- PMID: 16148178
- PMCID: PMC1235794
- DOI: 10.1128/CDLI.12.9.1104-1108.2005
Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies
Abstract
Three automated assays (Abbott AxSYM, Bayer ADVIA Centaur, and bioMerieux VIDAS) used for the detection of rubella virus-specific immunoglobulin M were evaluated. A total of 57 samples from individuals with evidence of infection with rubella virus were used to estimate sensitivity, and 220 samples from blood donors and individuals attending an antenatal clinic who had no evidence of recent infection were used to estimate specificity. Seroconversion panels comprising an additional 31 samples from four individuals were used to determine clinical sensitivity. Samples containing potentially cross-reacting substances were also tested. The sensitivities of the three assays ranged from 84.2 to 96.5%, and the specificities ranged from 96.8 to 99.9%. The Abbott AxSYM assay detected more reactive samples than the other two assays when a panel of 57 positive samples was tested. Bayer ADVIA Centaur detected more reactive samples in the seroconversion panels than the other two assays. All three assays evaluated reported a reactive result in 1 or more of the 48 samples containing potentially cross-reacting analytes. The assays demonstrated comparable performance in testing of a well-characterized panel of samples.
Similar articles
-
Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System.Clin Lab. 2004;50(1-2):63-73. Clin Lab. 2004. PMID: 15000222
-
Evaluation of the new ARCHITECT Rubella IgM assay.J Clin Virol. 2007 Jul;39(3):182-7. doi: 10.1016/j.jcv.2007.04.009. Epub 2007 May 31. J Clin Virol. 2007. PMID: 17543576
-
European performance evaluations of the ADVIA Centaur infectious disease assays: requirements for performance evaluation according to the European directive on in vitro diagnostics.J Clin Virol. 2004 Apr;30 Suppl 1:S6-10. doi: 10.1016/j.jcv.2004.02.003. J Clin Virol. 2004. PMID: 15062761
-
Evaluation of fully automated assays for the detection of Rubella IgM and IgG antibodies by the Elecsys(®) immunoassay system.J Virol Methods. 2014 Apr;199:108-15. doi: 10.1016/j.jviromet.2014.01.009. Epub 2014 Jan 30. J Virol Methods. 2014. PMID: 24487099
-
WHO international standard for anti-rubella: learning from its application.Lancet Infect Dis. 2020 Jan;20(1):e17-e19. doi: 10.1016/S1473-3099(19)30274-9. Epub 2019 Sep 6. Lancet Infect Dis. 2020. PMID: 31501007 Review.
Cited by
-
Hospital based surveillance of congenital rubella syndrome cases in the pre-vaccine era in Amhara Regional State, Ethiopia: A base line information for the country.PLoS One. 2018 Nov 12;13(11):e0207095. doi: 10.1371/journal.pone.0207095. eCollection 2018. PLoS One. 2018. PMID: 30419036 Free PMC article.
-
Evaluation of rubella virus immunoglobulin G (IgG) and IgM assays with the new Vidia instrument.J Clin Microbiol. 2008 May;46(5):1847-9. doi: 10.1128/JCM.00468-08. Epub 2008 Mar 26. J Clin Microbiol. 2008. PMID: 18367579 Free PMC article.
References
-
- Chernesky, M. A., L. Wyman, J. B. Mahony, S. Castriciano, J. T. Unger, J. W. Safford, and P. S. Metzel. 1984. Clinical evaluation of the sensitivity and specificity of a commercially available enzyme immunoassay for detection of rubella virus-specific immunoglobulin M. J. Clin. Microbiol. 20:400-404. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical